Leading experts engage in a comprehensive discussion on the intricate landscape of long-term remission and resistance patterns in transplanted acute myeloid leukemia (AML) patients, focusing on the potential role of Menin Inhibitor maintenance therapy. The dialogue delves into post-transplant outcomes and the emergence of resistance mutations, referencing previous presentations at the American Society of Hematology (ASH) meeting.
REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS
AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/
AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/
MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/
Central topics include the distinction between absolute and relative resistance, emphasizing multifaceted factors influencing resistance, from drug interactions to mutations. Data collection’s importance for comprehending Menin Inhibitors’ impact, especially when combined with other therapies, is highlighted.